JPWO2021119376A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021119376A5
JPWO2021119376A5 JP2022536653A JP2022536653A JPWO2021119376A5 JP WO2021119376 A5 JPWO2021119376 A5 JP WO2021119376A5 JP 2022536653 A JP2022536653 A JP 2022536653A JP 2022536653 A JP2022536653 A JP 2022536653A JP WO2021119376 A5 JPWO2021119376 A5 JP WO2021119376A5
Authority
JP
Japan
Prior art keywords
cancer cells
tumor vaccine
personalized
personalized tumor
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022536653A
Other languages
Japanese (ja)
Other versions
JP2023508852A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064412 external-priority patent/WO2021119376A1/en
Publication of JP2023508852A publication Critical patent/JP2023508852A/en
Publication of JPWO2021119376A5 publication Critical patent/JPWO2021119376A5/ja
Pending legal-status Critical Current

Links

Claims (27)

個別化腫瘍ワクチンであって、
（ａ）食作用刺激剤、
（ｂ）免疫賦活性アジュバント、および
（ｃ）弱毒化がん細胞
を含み、
それを必要とする個体に投与された場合、免疫応答を活性化するのに有効である、個別化腫瘍ワクチン。 A personalized tumor vaccine, comprising:
(a) a phagocytic stimulant,
(b) an immunostimulatory adjuvant; and (c) attenuated cancer cells;
A personalized tumor vaccine that is effective in activating an immune response when administered to an individual in need thereof. 弱毒化がん細胞が、個体の腫瘍から得られる、請求項１に記載の個別化腫瘍ワクチン。 2. A personalized tumor vaccine according to claim 1, wherein the attenuated cancer cells are obtained from an individual's tumor. 腫瘍が固形腫瘍および液体腫瘍からなる群から選択される、請求項２に記載の個別化腫瘍ワクチン。 3. A personalized tumor vaccine according to claim 2, wherein the tumor is selected from the group consisting of solid tumors and liquid tumors . 弱毒化がん細胞が、
（ａ）個体からの腫瘍部位の生検からがん細胞を採取すること、
（ｂ）採取されたがん細胞を療法上適切な量まで培養すること、および
（ｃ）培養されたがん細胞を照射すること
によって調製される、請求項１に記載の個別化腫瘍ワクチン。 Attenuated cancer cells
(a) obtaining cancer cells from a biopsy of a tumor site from an individual;
The personalized tumor vaccine according to claim 1, which is prepared by (b) culturing the collected cancer cells to a therapeutically appropriate amount; and (c) irradiating the cultured cancer cells. 弱毒化がん細胞が約１．０×１０３～約１．０×１０７個の量で存在する、請求項１に記載の個別化腫瘍ワクチン。 The personalized tumor vaccine of claim 1 , wherein the attenuated cancer cells are present in an amount of about 1.0 x 103 to about 1.0 x 107 . 食作用刺激剤がマンナンを含む、請求項１に記載の個別化腫瘍ワクチン。 2. A personalized tumor vaccine according to claim 1 , wherein the phagocytosis stimulant comprises mannan. 食作用刺激剤が、細胞膜修飾剤（ＢＡＭ）にコンジュゲートしている、請求項１に記載の個別化腫瘍ワクチン。 2. A personalized tumor vaccine according to claim 1 , wherein the phagocytosis stimulating agent is conjugated to a cell membrane modifier (BAM). ＢＡＭが、式Ｉ：
Figure 2021119376000001
を含み、式中、ｎは、ＰＥＧ鎖中のエチレンオキシド（ＥＯ）単位反復の数である、請求項７に記載の個別化腫瘍ワクチン。 BAM is of formula I:
Figure 2021119376000001
8. The personalized tumor vaccine of claim 7 , wherein n is the number of ethylene oxide (EO) unit repeats in the PEG chain. 免疫賦活性アジュバントがＴｏｌｌ様受容体（ＴＬＲ）アゴニストを含む、請求項１に記載の個別化腫瘍ワクチン。 2. The personalized tumor vaccine of claim 1 , wherein the immunostimulatory adjuvant comprises a Toll-like receptor (TLR) agonist. ＴＬＲアゴニストが、Ｒ－８４８、ポリ（Ｉ：Ｃ）、リポテイコ酸（ＬＴＡ）、またはそれらの組み合わせを含む、請求項９に記載の個別化腫瘍ワクチン。 10. The personalized tumor vaccine of claim 9 , wherein the TLR agonist comprises R-848, poly(I:C), lipoteichoic acid (LTA), or a combination thereof. 免疫賦活性アジュバントが抗ＣＤ４０抗体を含む、請求項１に記載の個別化腫瘍ワクチン。 2. The personalized tumor vaccine of claim 1 , wherein the immunostimulatory adjuvant comprises an anti-CD40 antibody. 免疫応答が、弱毒化がん細胞に特異的な適応免疫応答を含む、請求項１に記載の個別化腫瘍ワクチン。 2. A personalized tumor vaccine according to claim 1, wherein the immune response comprises an adaptive immune response specific for attenuated cancer cells. 個別化腫瘍ワクチンであって、
（ａ）マンナンであって、ＢＡＭにコンジュゲートしている、マンナン、
（ｂ）Ｒ－８４８、ポリ（Ｉ：Ｃ）およびＬＴＡ、
（ｃ）抗ＣＤ４０抗体、ならびに
（ｄ）照射がん細胞、
を含み、
それを必要とする個体に投与された場合、免疫応答を活性化するのに有効である、個別化腫瘍ワクチン。 A personalized tumor vaccine, comprising:
(a) mannan, which is conjugated to BAM;
(b) R-848, poly(I:C) and LTA,
(c) anti-CD40 antibody, and (d) irradiated cancer cells,
including;
A personalized tumor vaccine that is effective in activating an immune response when administered to an individual in need thereof. がんを治療する方法であって、それを必要とする個体に有効量の薬学的組成物を投与することを含み、薬学的組成物が、
（ａ）食作用刺激剤、
（ｂ）免疫賦活性アジュバント、および
（ｃ）弱毒化がん細胞
を含む、方法。 A method of treating cancer comprising administering to an individual in need thereof an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising:
(a) a phagocytic stimulant,
(b) an immunostimulatory adjuvant; and (c) an attenuated cancer cell. 弱毒化がん細胞が、個体の腫瘍から得られる、請求項１４に記載の方法。 15. The method of claim 14, wherein the attenuated cancer cells are obtained from an individual's tumor. 腫瘍が固形腫瘍および液体腫瘍からなる群から選択される、請求項１５に記載の方法。 16. The method of claim 15 , wherein the tumor is selected from the group consisting of solid tumors and liquid tumors . 弱毒化がん細胞が、
（ａ）個体からの腫瘍部位の生検からがん細胞を採取すること、
（ｂ）採取されたがん細胞を療法上適切な量まで培養すること、および
（ｃ）培養されたがん細胞を照射すること
によって調製される、請求項１４に記載の方法。 Attenuated cancer cells
(a) obtaining cancer cells from a biopsy of a tumor site from an individual;
15. The method according to claim 14 , which is prepared by: (b) culturing the collected cancer cells to a therapeutically appropriate amount; and (c) irradiating the cultured cancer cells. 弱毒化がん細胞が約１．０×１０３～約１．０×１０７個の量で存在する、請求項１４に記載の方法。 15. The method of claim 14 , wherein the attenuated cancer cells are present in an amount of about 1.0 x 103 to about 1.0 x 107 . 食作用刺激剤がマンナンを含む、請求項１４に記載の方法。 15. The method of claim 14 , wherein the phagocytosis stimulant comprises mannan. 食作用刺激剤が、細胞膜修飾剤（ＢＡＭ）にコンジュゲートしている、請求項１４に記載の方法。 15. The method of claim 14 , wherein the phagocytosis stimulating agent is conjugated to a cell membrane modifier (BAM). ＢＡＭが式Ｉ：
Figure 2021119376000002
を含み、式中、ｎは、ＰＥＧ鎖中のエチレンオキシド（ＥＯ）単位反復の数である、請求項２０に記載の方法。 BAM is of formula I:
Figure 2021119376000002
21. The method of claim 20 , wherein n is the number of repeating ethylene oxide (EO) units in the PEG chain. 免疫賦活性アジュバントがＴｏｌｌ様受容体（ＴＬＲ）アゴニストを含む、請求項１４に記載の方法。 15. The method of claim 14 , wherein the immunostimulatory adjuvant comprises a Toll-like receptor (TLR) agonist. ＴＬＲアゴニストが、Ｒ－８４８、ポリ（Ｉ：Ｃ）、リポテイコ酸（ＬＴＡ）、またはそれらの組み合わせを含む、請求項２２に記載の方法。 23. The method of claim 22 , wherein the TLR agonist comprises R-848, poly(I:C), lipoteichoic acid (LTA), or a combination thereof. 免疫賦活性アジュバントが抗ＣＤ４０抗体を含む、請求項１４に記載の方法。 15. The method of claim 14 , wherein the immunostimulatory adjuvant comprises an anti-CD40 antibody. 個別化腫瘍ワクチンが皮下投与される、請求項１４に記載の方法。 15. The method of claim 14 , wherein the personalized tumor vaccine is administered subcutaneously. 個別化腫瘍ワクチンが、弱毒化がん細胞に特異的な免疫応答を活性化することができる、請求項１４に記載の方法。 15. The method of claim 14 , wherein the personalized tumor vaccine is capable of activating an immune response specific to attenuated cancer cells. 免疫応答が適応免疫応答を含む、請求項２６に記載の方法。 27. The method of claim 26 , wherein the immune response comprises an adaptive immune response.
JP2022536653A 2019-12-11 2020-12-11 Personalized tumor vaccines and their use for cancer immunotherapy Pending JP2023508852A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962946934P 2019-12-11 2019-12-11
US62/946,934 2019-12-11
PCT/US2020/064412 WO2021119376A1 (en) 2019-12-11 2020-12-11 Personalized tumor vaccine and use thereof for cancer immunotherapy

Publications (2)

Publication Number Publication Date
JP2023508852A JP2023508852A (en) 2023-03-06
JPWO2021119376A5 true JPWO2021119376A5 (en) 2023-10-17

Family

ID=76330549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536653A Pending JP2023508852A (en) 2019-12-11 2020-12-11 Personalized tumor vaccines and their use for cancer immunotherapy

Country Status (7)

Country Link
US (1) US20230054318A1 (en)
EP (1) EP4072580A4 (en)
JP (1) JP2023508852A (en)
KR (1) KR20220141280A (en)
CN (1) CN114929265A (en)
AU (1) AU2020403013A1 (en)
WO (1) WO2021119376A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168761A1 (en) * 2020-03-19 2021-09-23 Minna HASSINEN Temperature-responsive virus storage system
US20240148855A1 (en) * 2021-03-18 2024-05-09 Ne1 Inc. Cancer vaccine and method of use thereof
CN115252782B (en) * 2022-07-28 2023-05-19 重庆医科大学 Oxygen-carrying bionic molecular probe, preparation method thereof and application thereof in HIFU and immune synergistic treatment of cancers
WO2024199557A1 (en) * 2023-03-29 2024-10-03 Biocanim A.S. A pharmaceutical combination for use in the treatment of cancer
CN117903980B (en) * 2024-01-05 2024-10-18 四川大学 Enterococcus hai and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370558B2 (en) * 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices

Similar Documents

Publication Publication Date Title
JP5539460B2 (en) Compositions and methods for cancer immunotherapy
KR101755526B1 (en) Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents
CN110121335A (en) Drug delivery composition and application thereof
TW200911274A (en) Alpha-galatosyl ceramide analogs and their use as immunotherapies
JP2009528267A (en) Glucan to enhance treatment
Jin et al. Preparation and evaluation of the adjuvant effect of curdlan sulfate in improving the efficacy of dendritic cell-based vaccine for antitumor immunotherapy
EP1625850B1 (en) Immunostimulating agents
US20060292163A1 (en) Phytol derived immunoadjuvants and their use in vaccine formulations
US20240156721A1 (en) Self-assembled nanoparticle releasing soluble microneedle structure and preparation method therefor
CN118286421A (en) Nanoparticles for use as therapeutic vaccines
TW202027786A (en) Immune inducer comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same
JP2015508811A (en) Use of tetrafunctional nonionic amphiphilic block copolymers modified by glycosylation as immune adjuvants
JPWO2021119376A5 (en)
Yu et al. Targeting strategies of liposomal subunit vaccine delivery systems to improve vaccine efficacy
CN112535735B (en) Combined medicine capable of simultaneously amplifying immunogenic cell death and enhancing anti-tumor effect
JP2020182486A5 (en)
JP2019172707A (en) Vaccine adjuvant composition based on amphiphilic polyamino acid polymer, containing squalene
JP2023073529A (en) complex
CN1341595A (en) Nonviscous protein type synthetic compound or its carrier combined compound
RU2779622C2 (en) Complex for enhancing immune response
RU2779622C9 (en) Complex for enhancing immune response
JP7296644B2 (en) Methods of preparing conjugates for enhancing immune responses
CN1647821A (en) Method for preparing specific nano vaccine for stomach cancer
Rosales-Mendoza et al. Nanogels-Based Mucosal Vaccines
CN115105526B (en) Application of modified PAMAM polymer in preparation of antitumor drugs